MX371277B - Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales. - Google Patents

Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales.

Info

Publication number
MX371277B
MX371277B MX2017008775A MX2017008775A MX371277B MX 371277 B MX371277 B MX 371277B MX 2017008775 A MX2017008775 A MX 2017008775A MX 2017008775 A MX2017008775 A MX 2017008775A MX 371277 B MX371277 B MX 371277B
Authority
MX
Mexico
Prior art keywords
resorption
maghemite
phosphate
drug based
simultaneous reduction
Prior art date
Application number
MX2017008775A
Other languages
English (en)
Other versions
MX2017008775A (es
Inventor
Wagner Susanne
Taupitz Matthias
Schnorr Jörg
Kratz Harald
EBER Monika
Stolzenburg Nicola
Gläser Janna
Hauptmann Ralf
BREINL Janni
Ariza DE SCHELLENBERGER Angela
GEMEINHARDT Ines
Original Assignee
Univ Berlin Charite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Berlin Charite filed Critical Univ Berlin Charite
Publication of MX2017008775A publication Critical patent/MX2017008775A/es
Publication of MX371277B publication Critical patent/MX371277B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Compounds Of Iron (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención comprende una sustancia basada en maghemita nanocristalina con un tamaño de cristal de entre 0,5 y 4 ran, que define un porcentaje de magnetita por el porcentaje de iones de hierro bivalentes menor de cinco de cien porcentajes en peso del hierro total y reduce el transporte de sodio y al mismo tiempo de fosfato en la pared estomacal e intestinal del contenido gastrointestinal en la circulación sanguínea y con ello puede mejorar el desequilibrio del balance de electrolitos, agua y minerales en el caso de una aplicación oral junto con coadyuvantes farmacéuticos adecuados.
MX2017008775A 2014-12-29 2015-12-28 Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales. MX371277B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014019388.8A DE102014019388A1 (de) 2014-12-29 2014-12-29 Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
PCT/DE2015/000608 WO2016107619A1 (de) 2014-12-29 2015-12-28 Arzneimittel auf der basis von maghämit zur gleichzeitigen reduzierung der gastrointestinalen natriumresorption und phosphatresorption

Publications (2)

Publication Number Publication Date
MX2017008775A MX2017008775A (es) 2018-03-23
MX371277B true MX371277B (es) 2020-01-24

Family

ID=55411127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008775A MX371277B (es) 2014-12-29 2015-12-28 Fármaco a base de maghemita para la reducción simultánea de la resorción de sodio y la resorción de fosfato gastrointestinales.

Country Status (11)

Country Link
US (1) US10632149B2 (es)
EP (1) EP3240531B1 (es)
JP (1) JP6676056B2 (es)
KR (1) KR102114827B1 (es)
CN (1) CN107257682B (es)
AU (1) AU2015373628B2 (es)
CA (1) CA2970754C (es)
DE (1) DE102014019388A1 (es)
MX (1) MX371277B (es)
WO (1) WO2016107619A1 (es)
ZA (1) ZA201704222B (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
DE19547356A1 (de) 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
CA2384429A1 (en) * 1999-09-14 2001-03-22 Michael K. Bahr Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
CA2426852C (en) * 2000-11-14 2010-01-26 Vital Health Sciences Pty Ltd Formulation containing phosphate derivatives of electron transfer agents
KR100487905B1 (ko) * 2002-10-02 2005-05-06 한국과학기술연구원 형상이방성 산화철 나노분말 및 그 제조방법
WO2005025508A2 (en) * 2003-09-12 2005-03-24 Bankruptcy Estate Of Ferx, Inc. Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
EP1738774A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren
WO2009040811A2 (en) * 2007-09-24 2009-04-02 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
AU2009334511C1 (en) 2008-12-31 2016-08-18 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10174203B2 (en) * 2009-06-26 2019-01-08 Merck Patent Gmbh Magnetic pigments comprising a flaky substrate and layer of maghemite
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN101985003A (zh) * 2010-11-18 2011-03-16 苏州市天灵中药饮片有限公司 一种具有补肾纳气功效的药酒
DE102011112898A1 (de) * 2011-09-08 2013-03-14 Charité - Universitätsmedizin Berlin Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
CN104225088A (zh) * 2014-10-06 2014-12-24 李先强 治疗慢性肺心病的混合中药

Also Published As

Publication number Publication date
EP3240531B1 (de) 2020-02-12
CN107257682A (zh) 2017-10-17
KR102114827B1 (ko) 2020-05-25
ZA201704222B (en) 2021-01-27
KR20170102901A (ko) 2017-09-12
DE102014019388A1 (de) 2016-06-30
CN107257682B (zh) 2021-03-02
CA2970754A1 (en) 2016-07-07
US20170348351A1 (en) 2017-12-07
CA2970754C (en) 2021-09-21
AU2015373628B2 (en) 2019-01-03
JP2018506516A (ja) 2018-03-08
US10632149B2 (en) 2020-04-28
JP6676056B2 (ja) 2020-04-08
MX2017008775A (es) 2018-03-23
AU2015373628A1 (en) 2017-07-13
WO2016107619A1 (de) 2016-07-07
EP3240531A1 (de) 2017-11-08

Similar Documents

Publication Publication Date Title
MX2020010607A (es) Compuestos y metodos para inhibir el transporte de fosfato.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
PL2753343T3 (pl) Kompozycja zawierająca n-acetylocysteinę oraz bakterie probiotyczne zdolne do przywrócenia własnego działania barierowego żołądka, które zostaje zniszczone podczas leczenia nadkwaśności soku żołądkowego inhibitorami pompy protonowej
IN2014DN06737A (es)
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
MX2017008775A (es) Farmaco a base de maghemita para la reduccion simultanea de la resorcion de sodio y la resorcion de fosfato gastrointestinales.
GB201208080D0 (en) Tobramycin formulation
NZ707033A (en) Dispersible nimorazole tablet
CL2020001926A1 (es) Uso de carbonato de calcio funcionalizado como ingrediente activo.
RU2014106575A (ru) Способ профилактики кровотечения при миомэктомии
DK201270714A (en) Dispersible tablet
Caocci Diarrhoea: case report
Qu Diarrhoea: case report
Tao Hypertension and neutropenia: case report
Cante Docetaxel/gemcitabine
MY194945A (en) Oral administration of unstable or poorly-absorbed drugs
Lesiak Adalimumab/infliximab/ustekinumab
UA83680U (ru) Способ комплексной реабилитации больных нейродермитом
UA94451U (uk) Спосіб профілактики системного остеопорозу у хворих на хронічне обструктивне захворювання легень
UA50311U (ru) Способ лечения хронического гиперацидного гастродуоденита у детей
UA85122U (ru) Способ медицинской реабилитации больных неалкогольным стеатогепатитом в сочетании с хроническим бронхитом на фоне ожирения
UA82673U (ru) Способ лечения нарушений консолидации переломов костей
UA67292U (ru) Способ комплексного лечения хронического панкреатита

Legal Events

Date Code Title Description
FG Grant or registration